Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NCT06029270 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

156

Enrollment

NIH

Sponsor class

Conditions

Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Scan
DRUG: Carboplatin
DRUG: Cisplatin
PROCEDURE: Computed Tomography
DRUG: Gemcitabine
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Nivolumab
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Relatlimab

Sponsor

National Cancer Institute (NCI)